Cortexyme (NASDAQ:CRTX) Share Price Crosses Above Two Hundred Day Moving Average - Should You Sell?

Key Points

• Shares of Cortexyme, Inc. (NASDAQ:CRTX) have crossed above their 200-day moving average of $1.37, reaching a high of $1.76 during trading.
• The stock is currently trading at $1.69 with a market cap of approximately $50.96 million and a P/E ratio of -0.57.
• Cortexyme is a clinical-stage biopharmaceutical company developing therapies for Alzheimer's disease and other degenerative diseases, with its lead candidate, atuzaginstat, in Phase II/III trials.

Cortexyme, Inc. (NASDAQ:CRTX - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.37 and traded as high as $1.76. Cortexyme shares last traded at $1.69, with a volume of 166,060 shares.

Cortexyme Stock Up 1.2%

The company's 50 day moving average price is $1.65 and its 200 day moving average price is $1.37. The firm has a market capitalization of $49.15 million, a price-to-earnings ratio of -0.55 and a beta of 1.40.

Cortexyme Company Profile

Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.